
By analyzing the mutation sites of N protein and their proportion according to the coronavirus sequences released by the GISAID database, full-length N protein recombinant antigens corresponding to VOC(Variants of Concern) and other mutant strains have been obtained as a mean to validate the current VYRA™ CoV2Flu antigen test’s sensitivity.
The testing variants includes:
- Omicron (B.1.1.529)
- Alpha (B.1.1.7+Q.x)
- Beta (B.1.351+B.1.351.2+B.1.351.3)
- Gamma (P.1+P.1.x)
- Delta(B.1.617.2+AY.x)
- VUM (B.1.640).
All antigens are tested positive. These results demonstrated VYRA™ CoV2Flu antigen test is capable in detecting each of the recombinant antigen of the listed variants.
About MedMira
MedMira is a leading developer and manufacturer of Rapid Vertical Flow Technology™ diagnostics. The Company’s tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as HIV, syphilis, hepatitis and SARS-CoV-2, in just three easy steps. The Company’s tests are sold globally under the Reveal®, REVEALCOVID-19®, Multiplo® and Miriad® brands. Based on its patented Rapid Vertical Flow Technology™, MedMira’s rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira’s corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit medmira.com. Follow us on LinkedIn, X and Youtube.
This news release contains forward‐looking statements, which involve risk and uncertainties and reflect the Company’s current expectation regarding future events, including statements regarding possible regulatory approval, product launch, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.